LIQUIK Study Interim Results to Showcase Lucence’s Liquid Biopsy Advancements at WCLC 2023
Precision medicine specialist Lucence, with a presence in Suzhou, Hong Kong, and Palo Alto, California,...
Precision medicine specialist Lucence, with a presence in Suzhou, Hong Kong, and Palo Alto, California,...
The State Administration for Market Regulation (SAMR) of China, in conjunction with nine other ministries,...
China-based Ascletis Pharma Inc. (HKG: 1672) announced the poster presentation of ASC42, a novel farnesoid...
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) presented updates on the clinical development of its...
China-based Keymed Biosciences Inc., (HKG: 2162) has announced that the latest results from a Phase...
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) presented updates on the clinical development of its...
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that its Category 1 drug...
CStone Pharmaceuticals’ (HKG: 2616) French partner, Servier, has published the latest results of the global...
China-based Zai Lab Ltd (ZLAB) (NASDAQ: ZLAB; HKG: 9688) and its partner Novocure Ltd (NASDAQ:...
China-based CStone Pharmaceuticals (HKG: 2616) announced that new data from a post hoc analysis of...
A number of Chinese pharmaceutical companies have shared updates on their pipeline developments at the...
Suzhou-based biotech firm Gracell Biotechnologies Inc., (Nasdaq: GRCL) has announced positive data for its pipeline...
Hangzhou-based biotech HighField Biopharmaceuticals has revealed the publication of an abstract at this year’s American...
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that its subsidiary, AlaMab Therapeutics Inc.,...
China-based Harbour Biomed (HKG: 2142) has announced the publication of results from a Phase Ib...
Shanghai Yizhong Pharmaceutical Co., Ltd (SHA: 688091), a China-based pharmaceutical company, has announced that clinical...
China-based BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) announced the presentation of new data at...
China-based urogenital cancer specialist Asieris Pharmaceuticals (SHA: 688176) has announced that it will publish the...
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that the results of three clinical...
China-based Innovent Biologics (HKG: 1801) has published the results of a Phase I clinical study...